lapatinib has been researched along with Bladder Cancer in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 16 (72.73) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Iio, A; Kaji, K; Maeda, S; Momoi, Y; Motegi, T; Nakazawa, M; Sakai, K; Yonezawa, T | 1 |
| Eriksson, P; Liedberg, F; Sjödahl, G | 1 |
| Ackerman, C; Gómez de Liaño, A; Powles, T | 1 |
| Crabb, SJ; Douglas, J; Hayden, A; Markham, H; Mora Vidal, R; Packham, G; Regufe da Mota, S | 1 |
| Chang, SS | 1 |
| Mu, Y; Sun, D | 1 |
| Becker, MN; Copland, JA; Kreinest, PA; Marlow, LA; Vonroemeling, CA; Williams, CR; Wu, KJ | 1 |
| Clozel, T; de Martino, M; Elemento, O; Klatte, T; Krzywinski, M; Rieken, M; Rouprêt, M; Shariat, SF; Xylinas, E; Zhuang, D | 1 |
| He, Z; Li, J; Li, X; Lin, B; Tang, X; Zhou, K | 1 |
| Airhart, S; Bult, C; Davis, RR; de Vere White, RW; Gandara, DR; Ghosh, PM; Gill, P; Keck, J; Lin, TY; Liu, E; Pan, CX; Tepper, CG; Zhang, H | 1 |
| Agerbaek, M; Cerbone, L; Collette, S; Daugaard, G; Marreaud, S; Sengeløv, L; Sternberg, CN; Van Herpen, C; Zhang, J | 1 |
| Guzzo, T; Keefe, S; Malkowicz, SB; Mamtani, R; Narayan, V; Vaughn, DJ | 1 |
| Ackerman, C; Beresford, M; Berney, D; Chester, J; Chowdhury, S; Crabb, S; Elliott, T; Frew, JA; Hilman, S; Huddart, RA; Hughes, S; Hussain, S; Jagdev, S; Jones, R; Macdonald, G; Powles, T; Santhanam, S; Sarker, SJ; Stockdale, A | 1 |
| Becker, M; Börgermann, C; Rose, A; Rübben, H; Vom Dorp, F | 1 |
| Griffiths, TR; Kriajevska, M; Manson, MM; McHugh, LA; Mejlvang, J; Mellon, JK; Sayan, AE; Sun, Y; Tulchinsky, E | 1 |
| Beuzeboc, P; De Groot, MR; El-Hariry, IA; Grimm, MO; Machiels, JP; Parikh, R; Pétavy, F; Richel, DJ; Treiber, U; Wülfing, C | 1 |
| Cheon, S; Cho, H; Espina, V; Havaleshko, DM; Lee, JK; Liotta, LA; Owens, CR; Petricoin, EF; Smith, SC; Theodorescu, D; Wulfkuhle, JD | 1 |
| Arranz, EE; Auñón, PZ; Barón, MG; Marín, AP; Sánchez, AR | 1 |
| Assaf, E; Bouaita, L; Culine, S; Delbaldo, C; Pouessel, D; Sellam, Z; Verlinde-Carvalho, M | 1 |
| Bristow, RG; Groselj, B; Kerr, M; Kiltie, AE; Knowles, MA; Phillips, RM; Qiao, B; Teo, MT | 1 |
| Chekaluk, Y; Du, J; Gray, NS; Guo, Y; Kwiatkowski, DJ; Wu, CL; Zhang, J | 1 |
| Griffiths, TR; Kriajevska, M; McHugh, LA; Mellon, JK | 1 |
1 review(s) available for lapatinib and Bladder Cancer
| Article | Year |
|---|---|
Role of anti-Her-2 therapy in bladder carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Models, Biological; Prognosis; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Urinary Bladder Neoplasms | 2010 |
6 trial(s) available for lapatinib and Bladder Cancer
| Article | Year |
|---|---|
Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; Lapatinib; Male; Muscles; Piroxicam; Protein Kinase Inhibitors; Receptor, ErbB-2; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
Topics: Animals; Female; Heterografts; Humans; Imidazoles; Lapatinib; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Pyridazines; Quinazolines; Quinolines; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Febrile Neutropenia; Female; Gemcitabine; Humans; International Cooperation; Lapatinib; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Renal Insufficiency; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lapatinib; Lymph Node Excision; Male; Maximum Tolerated Dose; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Humans; Lapatinib; Maintenance Chemotherapy; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Urinary Bladder Neoplasms | 2017 |
A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Transitional Cell; Disease Progression; Female; Humans; Lapatinib; Male; Middle Aged; Platinum Compounds; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2009 |
15 other study(ies) available for lapatinib and Bladder Cancer
| Article | Year |
|---|---|
Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Meta
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Double-Blind Method; ErbB Receptors; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Urinary Bladder Neoplasms | 2017 |
Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-lin
Topics: Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; ErbB Receptors; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms | 2018 |
Re: Phase III, Double-Blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-Line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
Topics: Double-Blind Method; Humans; Lapatinib; Receptor, ErbB-2; Receptors, Estrogen; Urinary Bladder Neoplasms | 2018 |
Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Female; Lapatinib; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Radiation Tolerance; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2018 |
The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.
Topics: Aged; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; Indoles; Lapatinib; Male; Purines; Quinazolines; Tissue Array Analysis; TOR Serine-Threonine Kinases; Triazines; Urinary Bladder Neoplasms | 2014 |
Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; In Vitro Techniques; Inhibitory Concentration 50; Lapatinib; Mutation; Quinazolines; Receptor, ErbB-2; Urinary Bladder Neoplasms | 2014 |
Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Genes, p53; Humans; Lapatinib; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms | 2015 |
[Targeted therapy for metastatic bladder cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Transitional Cell; Disease Progression; Drug Delivery Systems; Gefitinib; Humans; Lapatinib; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Sorafenib; Survival Rate; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Separation; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Humans; Inhibitory Concentration 50; Lapatinib; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome; Urinary Bladder Neoplasms | 2009 |
Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression; Gene Expression Profiling; Humans; Lapatinib; Models, Molecular; Oligonucleotide Array Sequence Analysis; Quinazolines; Sensitivity and Specificity; Signal Transduction; Urinary Bladder Neoplasms | 2009 |
Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Salvage Therapy; Urinary Bladder Neoplasms; Urologic Neoplasms | 2012 |
Imatinib radiosensitizes bladder cancer by targeting homologous recombination.
Topics: Antigens, Nuclear; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Homologous Recombination; Humans; Imatinib Mesylate; Ku Autoantigen; Lapatinib; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Rad51 Recombinase; Radiation-Sensitizing Agents; RNA Interference; Urinary Bladder Neoplasms | 2013 |
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
Topics: Afatinib; Antibiotics, Antineoplastic; Cell Line, Tumor; ErbB Receptors; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lapatinib; Loss of Heterozygosity; Naphthyridines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; Resorcinols; Signal Transduction; Sirolimus; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Cells, Cultured; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2013 |
Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Urinary Bladder Neoplasms | 2007 |